BigSur Wealth Management LLC Lowers Stock Position in Danaher Co. (NYSE:DHR)

BigSur Wealth Management LLC trimmed its position in Danaher Co. (NYSE:DHR) by 0.4% in the 4th quarter, HoldingsChannel reports. The fund owned 14,675 shares of the conglomerate’s stock after selling 60 shares during the quarter. Danaher makes up about 1.0% of BigSur Wealth Management LLC’s holdings, making the stock its 29th largest holding. BigSur Wealth Management LLC’s holdings in Danaher were worth $3,373,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Decker Retirement Planning Inc. purchased a new position in shares of Danaher in the fourth quarter valued at about $31,000. Teachers Insurance & Annuity Association of America bought a new stake in Danaher during the 3rd quarter valued at approximately $39,000. MidAtlantic Capital Management Inc. purchased a new position in Danaher in the 3rd quarter worth approximately $40,000. FSA Wealth Management LLC bought a new position in Danaher in the 3rd quarter worth approximately $50,000. Finally, Darwin Wealth Management LLC purchased a new stake in Danaher during the 3rd quarter valued at approximately $55,000. Institutional investors own 79.05% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on DHR. Bank of America raised shares of Danaher from a “neutral” rating to a “buy” rating and set a $290.00 target price for the company in a research note on Friday, December 13th. Stifel Nicolaus lifted their target price on Danaher from $250.00 to $265.00 and gave the stock a “hold” rating in a report on Wednesday, October 23rd. UBS Group dropped their price target on Danaher from $309.00 to $305.00 and set a “buy” rating for the company in a research note on Wednesday, October 23rd. StockNews.com downgraded Danaher from a “buy” rating to a “hold” rating in a research note on Saturday, December 14th. Finally, Stephens reiterated an “overweight” rating and set a $315.00 target price on shares of Danaher in a research report on Wednesday, October 23rd. Six equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $286.80.

Danaher Trading Down 1.4 %

Shares of NYSE DHR opened at $238.41 on Monday. Danaher Co. has a fifty-two week low of $222.53 and a fifty-two week high of $281.70. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.01 and a current ratio of 1.37. The company has a market cap of $172.20 billion, a price-to-earnings ratio of 45.50, a PEG ratio of 4.23 and a beta of 0.83. The business’s 50 day moving average price is $234.85 and its 200-day moving average price is $253.42.

Danaher (NYSE:DHR) last released its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, topping analysts’ consensus estimates of $1.57 by $0.14. The business had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.59 billion. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The business’s revenue was up 3.1% compared to the same quarter last year. During the same quarter last year, the firm posted $2.02 earnings per share. On average, sell-side analysts expect that Danaher Co. will post 7.49 earnings per share for the current year.

Danaher Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Friday, December 27th will be given a $0.27 dividend. The ex-dividend date is Friday, December 27th. This represents a $1.08 annualized dividend and a yield of 0.45%. Danaher’s dividend payout ratio (DPR) is 20.61%.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.